← brief for 2026-08-19 · Slowing decline

Glucagon-like peptide-1 receptor agonists for primary cardiovascular disease prevention in type 2 diabetes, a systematic review.

Article A Peer reviewed Meta-analysis or large trial

Key takeaways

This review pooled many randomized trials of GLP-1 drugs in people with type 2 diabetes who did not yet have heart disease. GLP-1 drugs are used for blood sugar and weight, and some also protect the heart and kidneys. It looked at whether they prevent heart and kidney problems before they start. Combining several large trials like this is the strongest kind of evidence.

Who did this work

Grenet G · Eskandari R · Ko J · Adams SP · Salzwedel DM · Heran BS · Ambasta A · Bassett K · Thompson W

Source

Article · PubMed, the drug frontier · 2026 Aug 19
https://pubmed.ncbi.nlm.nih.gov/42618306/